New York, N.Y., March 18, 2024 – PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights the FDA’s landmark approval
New York, N.Y., March 07, 2024 – PRISM MarketView announces the release of an insightful interview with Lipella Pharmaceuticals’ CEO, Dr. Jonathan Kaufman, discussing the
New York, N.Y., February 29, 2024 – PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies
New York, N.Y., February 01, 2024 – PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of
New York, N.Y., January 12, 2024 – In concert with Cervical Health Awareness Month, PRISM MarketView has added Verastem, Inc., a biopharmaceutical company focused on
October 11, 2023 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has reported two significant milestones this week as it pursues development of its drug candidate,
September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from
PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850
